Cadazolid for the treatment of Clostridium difficile

References

• Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin Infect Dis. 2012 Apr 4;55:216–223.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433–2441.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825–834.
   PubMed Web of Science ®Google Scholar
• Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. Toxins (Basel). 2010 Jul;2(7):1848–1880.
   PubMed Web of Science ®Google Scholar
• Darkoh C, Turnwald BP, Koo HL, et al. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr;21(4):509–517.
   PubMed Web of Science ®Google Scholar
• Dupont HL, Garey KW. Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol. 2010 Aug;5(8):1153–1156.
   PubMed Web of Science ®Google Scholar
• Garey KW, Jiang Z-D, Ghantoji S, et al. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15;51(12):1406–1410.
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010 Jan 21;362(3):197–205.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407–415.
   PubMed Web of Science ®Google Scholar
• Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec;66(12):2850–2855.
   PubMed Web of Science ®Google Scholar
• Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, et al. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis. 2016 Mar 01;62(5):574–580.
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010 May;31(5):431–455.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012 Apr;12(4):281–289.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 3;364(5):422–431.
   PubMed Web of Science ®Google Scholar
• Pham VP, Luce AM, Ruppelt SC, et al. Age-stratified treatment response rates in hospitalized patients with Clostridium difficile infection treated with metronidazole. Antimicrob Agents Chemother. 2015 Jul 20;59:6113–6116.
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005 Jun 01;40(11):1586–1590.
   PubMed Web of Science ®Google Scholar
• Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014 Aug;59(3):345–354.
   PubMed Web of Science ®Google Scholar
• Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012 Aug;55(Suppl 2):S93–S103.
   PubMed Web of Science ®Google Scholar
• Shah DN, Chan FS, Kachru N, et al. A multi-center study of fidaxomicin use for Clostridium difficile infection. Springerplus. 2016;5(1):1224.
   PubMed Web of Science ®Google Scholar
• Shah DN, Aitken SL, Barragan LF, et al. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul;93(3):286–289.
   PubMed Web of Science ®Google Scholar
• Aitken SL, Joseph TB, Shah DN, et al. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014;9(7):e102848.
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Reilly JP, Navalkele B, et al. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother. 2015 Nov;59(11):7007–7010.
   PubMed Web of Science ®Google Scholar
• Goldenberg SD, Brown S, Edwards L, et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis. 2016 Feb;35(2):251–259.
   PubMed Web of Science ®Google Scholar
• Michalska K, Karpiuk I, Król M, et al. Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem. 2013 Feb 1;21(3):577–591.
   PubMed Web of Science ®Google Scholar
• Locher HH, Seiler P, Chen X, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):892–900.
   PubMed Web of Science ®Google Scholar
• Baldoni D, Gutierrez M, Timmer W, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014 Mar;69(3):706–714.
   PubMed Web of Science ®Google Scholar
• Locher HH, Caspers P, Bruyère T, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):901–908.
   PubMed Web of Science ®Google Scholar
• Rashid M-U, Lozano HM, Weintraub A, et al. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe. 2013 Apr;20:32–35.
   PubMed Web of Science ®Google Scholar
• Rashid M-U, Dalhoff A, Weintraub A, et al. In vitro activity of MCB3681 against Clostridium difficile strains. Anaerobe. 2014 Aug;28:216–219.
   PubMed Web of Science ®Google Scholar
• Chilton CH, Crowther GS, Baines SD, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014 Mar;69(3):697–705.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Hecht DW, Louie T, et al. Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother. 2016 Jan;71(1):213–219.
   PubMed Web of Science ®Google Scholar
• Hubschwerlen C, Specklin J-L. 5-Hydroxymethyl-oxazolidinin-2-one-derivatives and their use as antibacterials. US8124623 B2 Feb 28, 2012. 2012.
   Google Scholar
• Baines SD, O’Connor R, Saxton K, et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother. 2009 Mar;63(3):520–525.
   PubMed Web of Science ®Google Scholar
• Gehin M, Desnica B, Dingemanse J. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection. Int J Antimicrob Agents. 2015 Nov;46(5):576–581.
   PubMed Web of Science ®Google Scholar
• Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015 Oct;59(10):6266–6273.
   PubMed Web of Science ®Google Scholar
• Knight-Connoni V, Mascio C, Chesnel L, et al. Discovery and development of surotomycin for the treatment of Clostridium difficile. J Ind Microbiol Biotechnol. 2016 Mar;43(2–3):195–204.
   PubMed Web of Science ®Google Scholar
• Boix V, Pesant T, Fegorak RN, et al. Primary clinical outcomes from a phase 3, randomized, double-blind, active-controlled study of surotomycin in patients with Clostridium difficile-associated diarrhoea. Presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2016; 2016; Amsterdam, Netherlands. Poster P0612.
   Google Scholar
• U.S. National Institute of Health Clinicaltrials.gov website. [cited 2016 Sep 19].  Available from https://clinicaltrials.gov/  Keyword search cadazolid.
   Google Scholar
• Chilton CH, Crowther GS, Todhunter SL, et al. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J Antimicrob Chemother. 2014 Sep;69(9):2426–2433.
   PubMed Web of Science ®Google Scholar
• Koo HL, Van JN, Zhao M, et al. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol. 2014 Jun;35(6):667–673.
   PubMed Web of Science ®Google Scholar